20 YEARS OF PROFESSIONAL & DEDICATED SERVICE TO GLOBAL CUSTOMERS

Custom Manufacturing, Project Outsourcing, your Trusted Partner from China

Optimizing Medical Imaging: The Role of DOTA as a Superior Chelator

The quest for enhanced visualization in medical diagnostics constantly drives innovation in contrast agent technology. For Magnetic Resonance Imaging (MRI), the development of stable and effective contrast agents is paramount, and DOTA (1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, CAS 60239-18-1) has emerged as a pivotal molecule in this area. Its superior chelating capabilities are what set it apart and make it a preferred choice for many leading contrast agents.

DOTA is a macrocyclic ligand, meaning its structure forms a ring that can tightly bind metal ions. Specifically, its four nitrogen atoms and four carboxylate groups create a cage-like structure that offers exceptional affinity and stability for paramagnetic ions like Gadolinium (Gd3+). This robust binding is crucial because free Gd3+ ions can be toxic. The macrocyclic nature of DOTA provides significantly higher thermodynamic stability and kinetic inertness compared to linear chelators, which are more prone to dissociating and releasing the metal ion. This means DOTA-based contrast agents offer a better safety profile and more reliable imaging results.

NINGBO INNO PHARMCHEM CO.,LTD. is committed to supplying the pharmaceutical industry with high-quality DOTA, a critical component for advanced MRI contrast agents. We ensure our DOTA, with a minimum purity of 98% and appearing as a white solid, meets the rigorous demands of this sector. Our competitive pricing and stable supply chain from China make us an ideal partner for manufacturers looking to purchase DOTA. By choosing NINGBO INNO PHARMCHEM, you are ensuring access to a reliable source of this essential pharmaceutical intermediate.

The molecular formula of DOTA (C16H28N4O8) and its molecular weight of 404.42 are key technical specifications that underscore its precise structure. Whether you are developing new contrast agents or ensuring the quality of existing ones, our DOTA can meet your needs. We invite you to contact us to learn more about our DOTA products and how we can support your critical research and development efforts in medical imaging.

Manufacturing Facilities

NINGBO INNO PHARMCHEM CO.,LTD. was established in 2007. It is committed to the R&D, production and sales of raw materials, pharmaceutical intermediates and fine chemicals. We striving to create a high-efficiency and high-quality integrated chemical service platform to better serve domestic and foreign customers.

Professional Export Experience

to Global Customers

WHY CHOSE US?

1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;

2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;

3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).

FAQ

  • A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.

  • A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.

  • A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.

CONTACT US
Should you need to contact us; you may call during regular business hours, Monday through Friday, 8am – 6 pm.
NINGBO INNO PHARMCHEM CO.,LTD.
Address: No.163 Ruiqing Rd.,Ningbo 315000 China
Phone: 86-574-87319282
Fax: 86-574-27912196
SEND US AN EMAIL

NAME*

EMAIL*

COMPANY

COUNTRY*

MESSAGE*

Previous: Understanding DOTA: Properties, Applications, and Manufacturing Insights

Next: The Strategic Importance of DOTA in Targeted Cancer Therapies

All Rights Reserved